At the news
? NEUTRALIMPACT 3/10 8-K filed Jul 27, 2026 at 09:08 ET
Sarepta Therapeutics appointed Michael Severino, M.D., as CEO effective July 28, 2026, succeeding Doug Ingram who is retiring and will serve as a consultant through December 31, 2026. Severino brings extensive R&D and leadership experience from AbbVie and Tessera Therapeutics, and will receive a compensation package including a $1.18M base salary, 110% target bonus, and a $35M sign-on equity grant.
- Michael Severino appointed CEO and Class I director effective July 28, 2026
- Douglas Ingram retires as CEO and board member, enters consulting agreement at $15,000/month through Dec 31, 2026
- Severino's base salary: $1,180,000 per year; target bonus: 110% of base salary
- Sign-on equity grant: ~$35,000,000 in RSUs and premium-priced stock options vesting over 4 years
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access